posted
CalbaTech's Subsidiary, LifeStem, Inc., Moving Forward With Its Stem Cell MicroBank(TM), Says Adult Stem Cell Research Promises Major Breakthroughs Feb 16, 2006 1:58:00 PM IRVINE, Calif., Feb. 16 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, said today that as its wholly owned subsidiary, LifeStem, Inc., begins the processes, procedures and protocols necessary to collect and store autologous stem cells at its Stem Cell MicroBank(TM), it is heartened by recent medical announcements that continue to show the enormous potential for healing through the use of adult stem cells.
"It was noted in the health media recently that, as few as five years ago, at an American Heart Association annual meeting, only five presentations spoke about the usefulness of stem cells to possibly repair diseased hearts," said Dan Fulkerson, President of LifeStem. "At the most recent heart association meeting, fully 25 percent of all papers presented were on this topic."
"The results showing that many heart-failure patients in clinical trials have benefited from adult stem cell treatments shows the promise of using stem cells in diseased hearts to create new, healthy tissue," Mr. Fulkerson said. "But this is only one of many research areas that have recently received widespread media attention."
LifeStem's President said that research in Chicago is showing that stem cells are causing remission against life-threatening, treatment resistant lupus, a chronic autoimmune disease mainly affecting women, and researchers at Rice University in Houston are showing how cultured adult stem cells can be made to grow new, healthy bone. Also, Indiana University School of Medicine scientists are involved in a clinical trial using stem cell injections to assist people with severe peripheral artery disease who face possible amputation because of poor blood circulation.
"We believe we are in exactly the right field at the right time with the opening of our Stem Cell MicroBank(TM) and we anticipate announcing further developments, and additional clients, in future months," Mr. Fulkerson said.
CalbaTech also today announced that the Company is now a part of Standard & Poor's Market Access Listing. Standard & Poor's is the world's foremost provider of independent indices, investment research, risk evaluation, independent credit ratings, data and valuation. It has played a leading role for more than 140 years in providing investors with independent benchmarks needed to feel confident about investment decisions. The link is at: http://reports.standardandpoors.com/aidata/maccess/c/clbe_374004_one.htm .
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. LifeStem, in addition to being the first company to offer micro collection of stem cells, is also the first company to offer a collection service that collects and stores two different types of stem cells. The Company has filed patent applications for an endoscopic stem cell delivery device and its novel Stem Cell MicroBank(TM) service.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com Note: Certain statements in this news release may contain "forward-looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
SOURCE CalbaTech, Inc.
---------------------------------------------- Paul Knopick of E&E Communications +1-949-707-5365 pknopick*eandecommunications.com for CalbaTech Inc.
-------------------- Before you criticize someone, try walking a mile in their shoes, then when you do, you'll be a mile away and have their shoes. Posts: 1450 | From: TX | Registered: Feb 2006
| IP: Logged |
posted
CalbaTech, Through Its Subsidiary, Lifestem, Inc., Enthusiastically Notes the Stem Cell Study Center to Be Established at USC; Lifestem is in the Exact Right Place for Stem Cell Services PR Newswire - February 27, 2006 05:00
IRVINE, Calif., Feb 27, 2006 /PRNewswire-FirstCall via COMTEX/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, said today that it believes that the announcement that the University of Southern California has received $25 million to construct a stem cell research facility at its medical school shows that Southern California will be the national leader for this cutting edge technology.
"We believe that this shows that LifeStem, Inc., our wholly owned subsidiary, which is in charge of our Stem Cell MicroBank(TM) Service for the collection of healthy adult stem cells for storage for potential future therapeutic use, is in the right place at the right time with the right product," said James DeOlden, CalbaTech CEO.
Previously, a state funding initiative approved by California voters established a state institute for stem cell research. "I believe that Southern California is going to be the hub for research that could give us answers for the treatment of diabetes, cardiovascular diseases and numerous other diseases," Mr. DeOlden said.
LifeStem recently announced an agreement with Solana MedSpas to offer its Stem Cell MicroBank(TM) Service to the spa customers and will be working to make the Stem Cell MicroBank(TM) Service the most available and acceptable two tissue adult stem cell banking service in the United States.
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. LifeStem, in addition to being the first company to offer micro collection of stem cells, is also the first company to offer a collection service that collects and stores two different types of stem cells. The Company has filed patent applications for an endoscopic stem cell delivery device and its novel Stem Cell MicroBank(TM) service.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements. Nothing in this release indicates any relationship whatsoever between CalbaTech, Inc., LifeStem, Inc., and the University of Southern California. Any belief or understanding based upon this release to the contrary is incorrect.
SOURCE CalbaTech, Inc.
Paul Knopick of E&E Communications for CalbaTech, Inc., +1-949-707-5365, pknopick*eandecommunications.com
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
